Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 513 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours MOST POPULAR New on NCI’s Websites, March 2020 March 16, 2020 Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... December 18, 2025 Load more HOT NEWS Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... Trial Results Support SBRT as a Standard Option for Some Prostate... Holiday Travel: 11 Things To Know Before Hitting The Road With...
